Kedrion Biopharma

Products of Kedrion are provided more than in 100 countries of the world, the company locates five production sites and is interested in deployment of production capacities in the Russian Federation. Within cooperation Kedrion will act as the technology partner, will transfer registration certificates, will perform a transfer of a line of medicines, will provide the platform with necessary production technologies, managements, control procedures, will organize a training of employees "Kirov Plasma" at the plants of the company.

Business in Russia

2017: Agreement signature about creation of JV Kirov Plazma

"The national immunobiological company", Pharmstandard and Kedrion Biopharma signed the agreement on creation of Kirov Plasma joint-stock company in March, 2017. The enterprise will develop and implements the program of production in the Russian Federation of the medicines received from plasma of blood of the person based on Kirov Plant. Kedrion Biopharma share in authorized capital makes 25%, Nacimbio and Pharmstandard – on 37.5% at each company. For more details see "Kirov Plasma".

Подписание проходило в здании Ростеха в присутствии генерального директора Госкорпорации Sergey Chemezov and acting as governor of the Kirov region Igor Vasilyev.

2016: The plan of creation of the joint venture with Nacimbio for production of medicines of plasma of blood

On June 17, 2016 it became known that (Nacimbio) entering into Rostec "National immunobiological company" agreed with the Italian company Kedrion about creation of the conscientious enterprise (CE) and purchase at Belarusian Pharmlend of a share in the Minsk enterprise for production of medicines of plasma of blood of the person. It is about total investments into 5.5 billion rubles.

As it appears from the message of Rostec, JV Nacimbio and Kedrion forms based on the Rosplazma complex in Kirov. Partners will be engaged in completion of construction of this plant on production of medicines of plasma. Production will be started in 2019 and will allow to process annually 600 tons of plasma. Investments into the project are estimated at 4 billion rubles.

Nacimbio invests 5.5 billion rubles in production of medicines of plasma of blood

"The plant in Kirov has a strategic importance for our holding and in general for the Russian health care which is in permanent dependence on foreign suppliers of medicines for patients with hemophilia, immunodeficient diseases, oncological patients — the head of Nacimbio  Nikolay Semyonov says. — To us it is extremely important that our partner – Kedrion company – is one of the largest processors of plasma in the world and totally can process up to 2.5 million liters of plasma annually. Besides, it is extremely important for us that our Italian partners not only provide technologies, but also invest money in construction of Kirov Plant".

After start of the enterprise in Kirov the current demand of domestic health care in albumine, immunoglobulin and substantially in fibrillation factors will be completely provided.

As for the plant in Minsk, in 2018 is going to begin industrial production of medicines there. At this stage production will allow to cover completely needs of citizens of Belarus for blood medicines (afterwards and needs of Russia). 1.7 billion rubles will be invested in this project.